MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers

PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data to support this approach. Here we describe a cohort of patien...

詳細記述

保存先:
書誌詳細
出版年:Mol Cancer Ther
主要な著者: Fricke, Stephanie L., Payne, Susan N., Favreau, Peter F., Kratz, Jeremy D., Pasch, Cheri A., Foley, Tyler M., Yueh, Alexander E., Van De Hey, Dana R., Depke, Mitchell G., Korkos, Demetra P., Sha, Gioia Chengcheng, DeStefanis, Rebecca A., Clipson, Linda, Burkard, Mark E., Lemmon, Kayla K., Parsons, Benjamin M., Kenny, Paraic A., Matkowskyj, Kristina A., Newton, Michael A., Skala, Melissa C., Deming, Dustin A.
フォーマット: Artigo
言語:Inglês
出版事項: 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363831/
https://ncbi.nlm.nih.gov/pubmed/30425131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0510
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料